causal
Medicare Part B reimbursement rewards expensive chemo
A fourth driver is that the system pays doctors more for more expensive treatment: under Medicare Part B, oncologists who buy and administer chemotherapy in their own offices are reimbursed average sales price plus 6%, so a 6% margin on a $6,000 drug like Abraxane is far larger than 6% on a $600 drug like Taxol, creating a financial pull toward the costlier option.
causalpending
Speaker
Vincent RajkumarEvidence Quote
“Our system rewards doctors more for the more expensive treatment”
Created: 6/13/2026, 12:13:30 AM
Your notes
Loading notes...